(NASDAQ: ERAS) Erasca's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.7%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.78%.
Erasca's earnings in 2026 is -$287,223,000.On average, 12 Wall Street analysts forecast ERAS's earnings for 2026 to be -$347,488,582, with the lowest ERAS earnings forecast at -$363,332,802, and the highest ERAS earnings forecast at -$315,835,118. On average, 12 Wall Street analysts forecast ERAS's earnings for 2027 to be -$221,539,273, with the lowest ERAS earnings forecast at -$274,213,435, and the highest ERAS earnings forecast at -$124,865,046.
In 2028, ERAS is forecast to generate -$266,693,552 in earnings, with the lowest earnings forecast at -$359,905,134 and the highest earnings forecast at -$224,022,583.